761 related articles for article (PubMed ID: 33746906)
1. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
2. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
Barb D; Bril F; Kalavalapalli S; Cusi K
J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827
[TBL] [Abstract][Full Text] [Related]
3. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
4. Circulating ectodysplasin A is a potential biomarker for nonalcoholic fatty liver disease.
Yang J; Zhou W; Zhu J; Wu Y; Xu L; Wang Y; Zhang Q; Yang Y
Clin Chim Acta; 2019 Dec; 499():134-141. PubMed ID: 31526774
[TBL] [Abstract][Full Text] [Related]
5. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.
Lomonaco R; Bril F; Portillo-Sanchez P; Ortiz-Lopez C; Orsak B; Biernacki D; Lo M; Suman A; Weber MH; Cusi K
Diabetes Care; 2016 Apr; 39(4):632-8. PubMed ID: 26861926
[TBL] [Abstract][Full Text] [Related]
7. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
8. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
Pais R; Charlotte F; Fedchuk L; Bedossa P; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
[TBL] [Abstract][Full Text] [Related]
10. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
[TBL] [Abstract][Full Text] [Related]
11. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
12. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
[TBL] [Abstract][Full Text] [Related]
13. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
14. Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease.
Liu Y; Chen H; Wang J; Zhou W; Sun R; Xia M
Am J Clin Nutr; 2015 Jul; 102(1):130-7. PubMed ID: 25948673
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz G
World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
[TBL] [Abstract][Full Text] [Related]
17. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity.
Jorge ASB; Andrade JMO; Paraíso AF; Jorge GCB; Silveira CM; de Souza LR; Santos EP; Guimaraes ALS; Santos SHS; De-Paula AMB
Obes Res Clin Pract; 2018; 12(Suppl 2):1-8. PubMed ID: 27083404
[TBL] [Abstract][Full Text] [Related]
18. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
[TBL] [Abstract][Full Text] [Related]
19. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
[TBL] [Abstract][Full Text] [Related]
20. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
